Trends in Extracorporeal Membrane Oxygenation Growth in the United States, 2011–2014

Abstract

The use of extracorporeal membrane oxygenation (ECMO) has grown rapidly in recent years. We sought to describe the rate of ECMO use in the United States, regional variation in ECMO use, the hospitals performing ECMO, and the primary payers for ECMO patients. Detailed data were obtained using the Healthcare Cost and Utilization Project (HCUPnet) summaries of State Inpatient Databases from 34 participating states for the years 2011–2014. The ECMO rates over time were modeled, overall and within subcategories of age group, bed size, hospital ownership, teaching status, and payer type. During the study period, the overall rate of ECMO use increased from 1.06 (1.01, 1.12) to 1.77 (1.72, 1.82) cases per 100,000 persons per year (p = 0.005). The rate of ECMO use varied significantly by region. Most ECMO patients are cared for at large hospitals, and at private, not-for-profit hospitals with teaching designation. The most common payer was private insurance; a minority of patient were uninsured. The use of ECMO increased significantly during the study period, but regional variation in the rate of ECMO use suggests that this technology is not being uniformly applied. Further research is warranted to determine why differences in ECMO use persist and what impact they have on patient outcomes.

Clinical Characteristics, Complications and Outcomes of Patients with Severe Acute Respiratory Distress Syndrome Related to COVID-19 or Influenza Requiring Extracorporeal Membrane Oxygenation—A Retrospective Cohort Study

“…Further comorbidities are displayed in Table 1 and Supplementary Table S1. The disease severities displayed by the median SAPS II, APACHE II and SOFA score on admission were 32 (28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41) vs. 27 (24-35.5) (p = 0.009), 17 (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23) vs. 18 (14-22) (p = 0.885) and 10 (9-13) vs. 10 (8-13) (p = 0.877), respectively.…”

Extracorporeal Membrane Oxygenation in Cardiogenic Shock due to Acute Myocardial Infarction: A Systematic Review

“…The use of ECMO in critical cases increased from 1.06 to 1.77 cases per 100,000 patients by 2014 in the USA and from 1.1 cases in 2007 to 6.2 cases in 2014 in Germany [29]. [17] NA NA Chang et al [18] NA NA Wu et al [19] 22 NA Chou et al [20] 15 NA Huang et al [21] 8 2 Sandoval et al [22] 16 5 Guenther et al [23] 15 3 Jeon et al [24] NA NA Fu et al [26] NA NA…”

Mesenchymal stem cells may ameliorate inflammation in an ex vivo model of extracorporeal membrane oxygenation

“…4 Similarly, in the last decade, extracorporeal membrane oxygenation (ECMO) has emerged as a life-saving means of providing temporary cardiorespiratory organ support to those whose condition is refractory to conventional management and is now firmly established as a management option in a wide range of critical illnesses. 5 Several of these, such as acute heart failure and acute respiratory distress syndrome (ARDS), are areas in which MSCs are being actively pursued as a novel therapeutic. Few studies of MSCs in conditions associated with critical illness have included patients on ECMO.…”